Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"

NCT02585804 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02585804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02585804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"
Lead sponsor
University Health Network, Toronto
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2015
Completion date
April 24, 2017
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal segmental glomerulosclerosis